INTS (Intensity Therapeutics, Inc.) יחס שווי שוק לשווי בספרים

The market capitalization trend for Intensity Therapeutics (INTS) stands at 1.02. Production capacities and laboratories are being utilized to their full extent to conduct antigen trials, eliminating any research pauses. Business revenues will be based on the sale of tumor-injectable agents that stimulate the fight against metastases. Management aims to integrate its innovative methods into standard therapy protocols for solid tumors.

For a fundamental valuation of Intensity Therapeutics (INTS), it is critical to compare its market status with its tangible assets. This ratio measures the equity value of the business by dividing the current market capitalization by the book value of equity. According to this chart of the market-to-book ratio, the current value is 1.02. Such a high valuation reflects investor expectations for the success of the INT230-6 technology in immuno-oncology; however, the significant gap between price and assets increases the risk of volatility.